GPR34激活可能连接淋巴上皮病变与唾液腺MALT淋巴瘤的发生
唾液腺MALT淋巴瘤特异性关联GPR34易位和突变,突变多聚集于C端导致截短蛋白。体外实验显示GPR34 Q340X截短突变较野生型显著抵抗凋亡、转化潜能增强,内化延迟,并激活CRE、NF-κB和AP1报告活性。表达Q340X的细胞培养上清中磷脂酶A1/2活性增强,可催化磷脂酰丝氨酸生成溶血磷脂酰丝氨酸。磷脂酶A1在唾液腺导管上皮及淋巴上皮病变中高表达,提示旁分泌刺激模型。
要点
- GPR34 Q340X截短突变较野生型显著抵抗凋亡并增强转化潜能。
- Q340X突变延迟受体内化,并激活CRE、NF-κB和AP1信号通路。
- 淋巴上皮病变释放磷脂酶A生成GPR34配体,旁分泌刺激恶性B细胞。
核心结论
- GPR34激活可能通过淋巴上皮病变释放磷脂酶A生成溶血磷脂酰丝氨酸,旁分泌刺激恶性B细胞,桥接淋巴上皮病变与唾液腺MALT淋巴瘤发生。
研究设计与样本
- 构建稳定表达单拷贝GPR34野生型或Q340X、R84H、D151A突变体的Flp-InTRex293同源细胞系,进行系列体外实验。
主要发现
- GPR34 Q340X截短突变而非R84H和D151A突变,较野生型显著增加抗凋亡能力和转化潜能。
- 配体溶血磷脂酰丝氨酸刺激后,GPR34截短突变体内化较野生型显著延迟。
- 在9条检测信号通路中,Q340X截短突变显著激活CRE、NF-κB和AP1报告活性,D151A突变激活程度较低,配体刺激下尤为明显。
- 表达Q340X突变体的Flp-InTRex293细胞培养上清中磷脂酶A1/2活性增强,具有催化磷脂酰丝氨酸合成溶血磷脂酰丝氨酸的潜力。
- 磷脂酶A1在唾液腺导管上皮及淋巴上皮病变中丰富表达。
临床怎么用
- 提示GPR34突变状态或可辅助识别唾液腺MALT淋巴瘤,但尚需临床验证。
- 磷脂酶A1/溶血磷脂酰丝氨酸/GPR34轴为潜在干预靶点,目前仅为体外证据。
局限性
- 研究基于Flp-InTRex293细胞系体外实验,尚未在原代肿瘤细胞或动物模型中验证。
- GPR34突变促进淋巴瘤发生的体内因果证据未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
GPR34 translocation and mutation are specifically associated with salivary gland MALT lymphoma (SG-MALT-lymphoma). The majority of GPR34 mutations are clustered in its C-terminus, resulting in truncated proteins lacking the phosphorylation motif important for receptor desensitization. It is unclear why GPR34 genetic changes associate with SG-MALT-lymphoma and how these mutations contribute to the development of lymphoma. We generated isogenic Flp-InTRex293 cell lines that stably expressed a single copy of GPR34 or its various mutants and performed a range of in vitro assays. We found that the GPR34 Q340X truncation, but not the R84H and D151A mutants, conferred a significantly increased resistance to apoptosis and greater transforming potential than the GPR34 wild type. The GPR34 truncation mutant had a significantly delayed internalization compared with the wild type after ligand (lysophosphatidylserine) stimulation. Among the 9 signaling pathways examined, the GPR34 Q340X truncation, and to a lesser extent the D151A mutant, significantly activated CRE, NF-κB, and AP1 reporter activities, particularly in the presence of ligand stimulation. We further described the enhanced activities of phospholipase-A1/2 in the culture supernatant of Flp-InTRex293 cells that expressed the GPR34 Q340X mutant, as well as their potential to catalyze the synthesis of lysophosphatidylserine from phosphatidylserine. Importantly, phospholipase-A1 was abundantly expressed in the duct epithelium of salivary glands and those involved in lymphoepithelial lesions (LELs). Our findings advocate a model of paracrine stimulation of malignant B cells via GPR34, in which phospholipase A is released by LELs and hydrolyzes the phosphatidylserine exposed on apoptotic cells, generating lysophosphatidylserine, the ligand for GPR34. Thus, GPR34 activation potentially bridges LELs to genesis of SG-MALT-lymphoma.
引用
- Korona B, Korona D, Zhao W, et al. GPR34 activation potentially bridges lymphoepithelial lesions to genesis of salivary gland MALT lymphoma. Blood. 2022. PMID: 34086889. doi:10.1182/blood.2020010495
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。